Objectives: Extended-spectrum b-lactamase (ESBL)-producing Escherichia coli (ESBLEC) is an increasingly significant cause of community-acquired infection worldwide. The epidemiological features of CTX-M-and SHV-producing ESBLEC causing community-acquired infections are compared.
Introduction
Community-acquired infections caused by extended-spectrum b-lactamase (ESBL)-producing Escherichia coli (ESBLEC) are increasing worldwide. 1 Urinary tract infections (UTIs) are the most prevalent, although other types of infection, including bacteraemia, have been described. In recent years, important shifts have occurred, both in Europe and in other continents, in the prevalence and types of ESBL, with the classic SHV and TEM types of ESBL being surpassed by members of the CTX-M family. 2 The epidemiology of both ESBLEC and plasmids carrying the bla genes is complex, combining the dissemination of mobile genetic elements and clonal spread. Food, and particularly poultry, has been considered a potential source of these enzymes. 3 In addition, both plasmids and bacterial transmission between closely related humans have also been demonstrated. 4 Finally, the intercontinental emergence of clonally related isolates harbouring particular ESBLs such as CTX-M-15 has been recently described in many countries. 5 Among the risk factors for acquiring a community-acquired infection caused by ESBLEC are recent antibiotic therapy, recent hospitalization, surgery and male gender. 6 Most of these studies have included cases caused by E. coli expressing different ESBL families but with a clear preponderance of the CTX-M family. In fact, the dissemination of ESBLs among E. coli within the community has been linked almost exclusively with CTX-M enzymes. This fact might have led to an underestimation of the importance of other ESBLs, including SHV enzymes, in community-acquired infections caused by ESBLEC. In a previous study in Spain, an SHV-type enzyme was involved in 30% of infections caused by ESBLEC.
7 CTX-M-14, followed by SHV-12, was the most frequently found enzyme in non-hospitalized infections caused by ESBLEC. Moreover, the SHV-type ESBL was the most common enzyme detected in E. coli isolates found in some retail raw meat samples in southern Spain. 8 Despite these facts, there is still scarce information about the epidemiology of the SHV-type ESBL in the community. The purpose of this study was to compare the epidemiological features of community-acquired infections caused by CTX-M-and SHV-producing E. coli in a multicentre nationwide study performed in Spain.
Materials and methods
The study sites, subjects, design and definitions of the study were specified previously. 6 In brief, a prospective laboratory-based cohort was conducted between February 2002 and May 2003 in 11 public Spanish hospitals serving a population of .4 million people, located in five Spanish areas including Barcelona (north-east), Madrid (central), Majorca and Valencia (east) and Seville (south). All patients in the participating hospitals with a clinical sample from which an ESBLEC strain had been isolated were considered to be eligible. Patients who had been hospitalized for more than 48 h when the sample was collected, those who had been admitted to a hospital for .48 h during the preceding month and those with a previous isolation of ESBLEC were excluded. Demographic data, predisposing conditions, invasive procedures, previous healthcare contact and infection type were collected. The study protocol was approved by the ethics committees of the participating centres.
Further to the microbiological determinations described in the previous study, 6 the clonal relationship between the isolates was determined by repetitive extragenic palindromic PCR (REP-PCR), as described previously. 7 Isolates that were determined to be clonally related by REP-PCR were also studied by PFGE.
7 b-Lactamase characterization was carried out by isolectric focusing (Pharmacia Phastsystem) of the sonicated extract, and PCR of the bla genes. 9 Amplicons were further sequenced for the final characterization of the bla gene. 9 Univariate comparisons were performed using the MannWhitney U-test and x 2 test (or Fisher's exact test) for continuous and discrete variables. Multivariate analyses were performed by logistic regression using a backward stepwise process. Interactions between paired variables were investigated. Data were analysed using the SPSS 13.0 software package.
Results
A total of 122 cases was included; the 112 cases in which the ESBLs were characterized were included in this analysis. The CTX-M ESBL was detected in 77 isolates (69%). Of these, 65 belonged to the CTX-M-9 group (40 CTX-M-9 and 25 CTX-M-14), 9 to the CTX-M-1 group (4 CTX-M-32, 2 CTX-M-3, 2 CTX-M-15 and 1 CTX-M-1) and 3 were not sequenced. Thirty-six (32%) belonged to the SHV family (31 SHV-12 and 5 SHV-2) and 7 (6%) belonged to the TEM family (4 TEM-116, 2 TEM-52 and 1 TEM-4). Eight isolates produced more than one ESBL. The percentage of isolates producing SHV enzymes was 22% in the north-east (5/23), 26% in the central area (7/27), 36% in the south (16/44) and 44% in the east (8/18). Clonal relationships were few since 107 REP-PCR patterns were obtained.
For further analysis, cases of E. coli expressing only the CTX-M and SHV ESBLs (70 and 31 patients, respectively) were compared. The univariate analysis of microbiological features is shown in Table 1 . Among them cefotaxime susceptibility was significantly higher in SHV-producing isolates and ceftazidime susceptibility was significantly higher in CTX-M producers, as expected. No significant differences with other antimicrobial agents were observed.
Predisposing factors by ESBL family were also evaluated. In the univariate analysis, only the severity of the underlying chronic condition was significantly different between both groups; the frequency of a Charlson Index .2 was significantly higher in the SHV group. There were no significant differences observed for the other variables evaluated. More precisely, the percentage of cases with no significant previous healthcare relation (70% for CTX-M cases and 68% for SHV cases) was similar. When a multivariate analysis was performed, the only variables independently associated with SHV-producing isolates were a Charlson Index score of .2 [OR (95% CI) ¼ 4.0 (1.2 -12.6), P¼ 0.01] and age .60 years as a protective factor [OR (95% CI) ¼ 0.2 (0.08 -0.5), P ¼ 0.002]. No differences were found for type of infection caused by SHV and CTX-M producers; UTIs were the most prevalent infection (97% and 94%, respectively). No patients died.
Discussion
ESBLEC is an increasingly relevant group of community pathogens worldwide. In the last few years, ESBL patterns have been changing rapidly with CTX-M enzymes replacing TEM and SHV mutants as the predominant ESBLs in many European countries. 2 Most of these infections were associated with clonally unrelated isolates, but, more recently, E. coli O25:H4-ST131 has been recognized as an emerging international clone group expressing specific ESBLs such as CTX-M-15. 5 A case -control case study was performed in 11 hospitals in Spain to investigate the risk factors for all types of communityacquired infection caused by ESBLEC. 6 In predisposed patients, ESBLEC was a notable cause of community-acquired infections, particularly UTIs. The estimated population-based incidence of community-acquired infections caused by these microorganisms was 2.2 cases per 100000 population per year. Risk factors associated with infection were: age .60 years, female sex, diabetes mellitus, recurrent UTI, previous invasive procedures of the urinary tract, and previous receipt of antimicrobials. 6 In that study, all ESBLECs were considered globally, and the results were not stratified by type of ESBL, since this information was unavailable at the time. In this and other studies developed in Spain, around 30% of infections caused by ESBLEC involved an SHV-type enzyme, and the most prevalent was SHV-12. 6, 7 Because of the emergence of infections caused by CTX-M-producing isolates, the importance of SHV-producing E. coli as a cause of community-acquired infections may be being underestimated.
In this study, the epidemiological and clinical data of community-acquired infections caused by CTX-M-and SHVproducing E. coli were compared. No relevant differences were observed between the two groups. Features associated with SHV-producing isolates were age .60 years ( protective) and a more severe underlying disease. Of note, previous use of antibiotics, and particularly fluoroquinolones, was similar in both groups, reflecting their similarly high frequency of resistance to these compounds. Since no relevant differences were found between the two groups of isolates, it might be speculated that the risk factors for acquiring infections by CTX-M-and SHV-producing E. coli could also be similar. Food of animal origin has been demonstrated to favour the dissemination of ESBLEC. 3 In some areas of Spain, the SHV-type enzyme was the most prevalent ESBL found in E. coli isolated from raw poultry meat. 8 Moreover, the overall prevalence of faecal carriage of ESBLEC within the community was 67.9% in patients with UTI caused by this microorganism, 27.4% in household members, 15.6% in non-household members and 7.4% in unrelated patients. 4 In these groups, the percentages of SHV-producing E. coli from the total were 33.3%, 50%, 60% and 75%, respectively. All these data together suggest that both acquisition from a common source and person-to-person transmission may contribute to ESBL dissemination, including that of SHV-type enzymes. In recent years, the dissemination of CTX-M-producing isolates has expanded rapidly as a consequence of the international clonal dissemination of E. coli O25:H4 and others harbouring mainly the CTX-M-15 enzymes. 5 A diversity of plasmid incompatibility groups harbouring ESBL genes and substantial variability in the genetic environment have been documented in Spain. 10 Since some of the characterized plasmids carrying CTX-M genes belong to the same incompatibility groups as those described for SHV-12, such as Incl1, the possibility of a potential epidemic dissemination of specific plasmids encoding SHV-type ESBLs in E. coli could not be ruled out.
In conclusion, SHV-producing ESBLEC is a significant cause of community-acquired infection in Spain; the clinical epidemiology of these isolates seems very similar to that of CTX-M-producing ESBLEC. The data suggest that SHVproducing E. coli are also spreading in the community. 
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